To better understand the performance of plasma P‐tau181 to monitor tau pathology and subsequent neurodegeneration in AD, we need truly longitudinal analyses that incorporate change of both neuroimaging measures and P‐tau181. Here, MAPT is linked to Alzheimer disease.